Melinta Therapeutics, Inc. (NASDAQ:MLNT)

13.00
Delayed Data
As of Feb 16
 -0.20 / -1.52%
Today’s Change
10.25
Today|||52-Week Range
24.25
-17.72%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 4
2016
Quarter 1
2017
Quarter 2
2017
Quarter 3
2017
Revenue and IncomeNet Revenues7.9M4.9M860.0K1.7M
 
 
 
 
 
Depreciation And Amortization11.0K9.0K6.0K6.0K
 
 
 
 
 
 
Operating ExpensesGross Income----------
General Expenses39.2M24.2M13.2M12.2M
 
 
 
 
 
Research And Development21.0M15.4M8.5M4.4M
 
 
 
 
 
Total Operating Expenses39.2M24.2M13.2M12.3M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-31.3M-19.3M-12.3M-10.5M
 
 
 
 
 
Extraordinary Charge0.00-3.6M----
 
 
Interest Expense On Debt280.0K243.0K226.0K208.0K
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-31.4M-22.9M-12.3M-10.4M
 
 
 
 
 
Net Income-31.4M-22.9M-12.3M-10.4M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS10.5M10.5M10.5M10.5M
 
 
 
 
 
Shares To Calculate EPS Diluted10.5M10.5M10.5M10.5M
 
 
 
 
 
 
Earnings Per ShareEPS-$3.00-$2.20-$1.15-$1.00
 
 
 
 
 
EPS Diluted-$3.00-$2.20-$1.15-$1.00